Q4 2024 Earnings Call Transcript April 10, 2025 CureVac N.V. misses on earnings expectations. Reported EPS is $-0.16564 EPS, ...

In the default model, the graph representing each individual enhancer can be arbitrarily complicated. To show how the ABC Score formula can arise from the default model, we need to impose the further ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicine company ...

Writing in Molecular Therapy Nucleic Acids, researchers hypothesized that using poly(A) tail mimetics to enhance mRNA expression from haploinsufficiency-associated genes could be a disease-modifying ...

Combining mRNA with a specialised lipid nanoparticle could reach areas of the lungs previously inaccessible to conventional ...

Ethris has partnered Lonza for the development of room-temperature stable mRNA vaccine candidates targeting respiratory ...

The FDA has granted clearance to CureVac's IND for the open-label Phase I trial of CVHNLC in individuals with sqNSCLC.

Esophageal basaloid squamous cell carcinoma (EBSCC) is a rare type of esophageal squamous cell cancer (ESCC) characterized by basaloid features and considered to be more aggressive than ESCC. RNA ...

Discover how an emerging technology called tRNA therapy could become the next big thing in genetic disease treatment.

Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Lonza, one of the world's largest contract development and manufacturing organizations ...

为探究 FSH 对内皮 - 间质转化（EndMT）的影响，广州医科大学研究人员以 ApoE -/- 小鼠和人脐静脉血管内皮细胞（HUVECs）为模型展开研究。结果表明 FSH 可促进 EndMT，这为预防绝经女性急性冠状动脉综合征提供新思路。

Wacker Biotech announced a strategic collaboration with RNAV8 Bio, a pioneer in mRNA engineering for the development of ...